CD81 protein in untreated myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a protein called CD81 in people with newly diagnosed myeloid leukemia who have not yet been treated. The goal is to see if CD81 levels can help doctors understand more about the disease and possibly guide future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myeloid leukemia (like acute or chronic myeloid leukemia).
- You have not started any treatment yet for this leukemia.
- You do not have another type of blood cancer (like ALL, CLL, or myeloma).
- You have not had any other cancer in the past or present.
- This must be your first diagnosis of leukemia (not a relapse).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
This study looks at two markers (CD38 and CD56) on cells from people with chronic myeloid leukemia (CML). It may help doctors understand the disease better and could guide treatment choices in the future.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.